Search results
Merck stopped a clinical trial for its experimental skin cancer drug after a high rate of side...
Quartz· 3 days agoThe study was testing whether a combination of the company’s flagship cancer drug Keytruda and its...
Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study
Morningstar· 3 days agoMerck & Co. has ended part of a late-stage study of a co-formulation of its blockbuster cancer drug Keytruda in certain skin-
2 No-Brainer Dividend Stocks to Buy in May
Motley Fool via Yahoo Finance· 7 days agoThe oncology market is known for its strong pricing power, with cancer drugs typically carrying high price tags and significant margins. While Pfizer's...
...Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles...
Yucaipa News Mirror· 6 days agoAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced ...
Moderna Stock Rebounds From Its RSV Vaccine Fallout — Is It A Buy, Again?
Investor's Business Daily· 2 days agoPreviously, the FDA expected to make it decision by May 12. Moderna emphasized the FDA has not...
Top Stock Reports for Broadcom, Merck & Airbnb
Zacks via Yahoo Finance· 12 hours agoToday's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Merck & Co., Inc. (MRK) and Airbnb, Inc. (ABNB).
The doctor behind the next big thing in cancer treatment
CNN via AOL· 6 days agoDr Catherine Wu’s research has laid the scientific foundation for the development of cancer vaccines...
Blockbuster Drug Patent Thickets Signal 'Strategic Behavior'
MedPage Today· 3 days agoAn analysis of patent applications for 10 top-selling prescription drugs found that nearly...
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results
Morningstar· 1 day agoKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced ...
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 6 days agoCytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript May 8, 2024 CytomX...
